• TRM (USD/COP)COP 3,461.92 +1.37% +COP 46.82Colombia's official exchange rate (Financial Superintendence), valid Nov 21 to Nov 23
  • EuroCOP 3,804.64 +1.37% +COP 51.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote
  • Mexican pesoCOP 181.56 +1.37% +COP 2.45Reference: TRM crossed with the European Central Bank rate of Nov 20; not the market quote

Iovance falls on Wall Street after new doubts about the durability of its experimental lung cancer treatment

FinanceInternationalInvestor's Business Daily20 s readAI summary
Image: Investor's Business Daily

Iovance shares plunged on Thursday and lost their 50-day moving average, according to Investor's Business Daily, after new questions emerged about the durability of its experimental lung cancer treatment. The outlet describes Iovance as a top 1% biotech stock.

In 20 seconds

  • Iovance fell sharply in Thursday's session.
  • The drop took the stock below its 50-day moving average.
  • The trigger was new doubts about the durability of its experimental lung cancer treatment.
Read the full story at Investor's Business Daily

IASummary generated by artificial intelligence from a story by Investor's Business Daily. It may contain errors: the original source prevails.

Comments

Be respectful. Comments reported by several people are hidden until a moderator reviews them.

You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.

    Keep reading